Journal Article Ahead of print
PubMed: 41102880 DOI: 10.1093/cid/ciaf579
Absolute and Relative Effectiveness of Cell- and Egg-based Quadrivalent Inactivated Influenza Vaccine Products from 2014-2015 to 2018-2019 seasons, U.S. Flu VE Network.
Clin Infect Dis
Authors: Manjusha Gaglani, Chandni Raiyani, Kempapura Murthy, Michael Smith, Briget da Graca, Gueorgui Dubrocq, Madhava Beeram, Emily T Martin, Arnold S Monto, Richard K Zimmerman, Mary Patricia Nowalk, Erika Kiniry, C Hallie Phillips, Huong Q Nguyen, Jennifer P King, Sara S Kim, Jessie R Chung, Brendan Flannery
Affiliations
- Baylor Scott & White Health, Temple, TX, USA.
- Baylor College of Medicine, Temple, TX, USA.
- Baylor Scott & White Health, Temple, TX, USA. Baylor College of Medicine, Temple, TX, USA.
- University of Michigan School of Public Health, Ann Arbor, MI, USA.
- University of Pittsburgh, Schools of Health Sciences, Pittsburgh, PA, USA.
- Kaiser Permanente Washington Health Research Institute, Seattle, WA, USA.
- Marshfield Clinic Research Institute, Marshfield, WI, USA.
- Influenza Division, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Abstract
BACKGROUND
Estimates of annual effectiveness of influenza vaccination combine multiple vaccine types. Reports of brand/product-specific vaccine effectiveness (VE) of egg- and cell-culture based quadrivalent inactivated influenza vaccines (IIV4/ccIIV4) are limited.
METHODS
Using an observational test-negative study design, we compared effectiveness of selected IIV4 and ccIIV4 products among outpatients enrolled in the US Flu VE Network from 2014-2015 to 2018-2019. We used multivariable logistic regression to estimate product- and age-group-specific absolute and relative effectiveness of recommended, age-appropriate vaccines against symptomatic laboratory-confirmed outpatient influenza. Relative effectiveness of ccIIV4 versus IIV4 products was estimated during two seasons from 2017-2019 among participants aged ≥4 years.
RESULTS
Pooling data from five influenza seasons when 18% and 15% of vaccinated patients had received Fluarix® Quadrivalent or Fluzone® Quadrivalent IIV4, respectively, VE against influenza was 32% for Fluarix IIV4 and 37% for Fluzone IIV4. Pooling two seasons when 11% and 28% of vaccinated patients had received ccIIV4/Flucelvax® Quadrivalent and FluLaval® Quadrivalent IIV4, respectively, VE against influenza for each product was 30%. Absolute VE compared to unvaccinated patients was lowest against influenza A(H3N2) compared to that against A(H1N1)pdm09 and each B lineage; VE point estimates were lowest among patients aged ≥50 years compared to two younger age-groups. Relative effectiveness estimates were not statistically significant, indicating similar protection across vaccine products.
CONCLUSION
Comparisons of influenza vaccine products over multiple seasons showed benefit against symptomatic laboratory-confirmed outpatient influenza of both egg- and cell culture-based quadrivalent inactivated influenza vaccines, with similar absolute and relative levels of protection provided by each product.
MeSH
Cells, Laboratories, Vaccines, Aged, Influenza, Human, Influenza Vaccines, Outpatients, Communicable Diseases